Sign-up for VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity investment picks
MOUNTAIN VIEW, CA and CHESTERBROOK, PA--(Marketwired - September 18, 2014) - VIVUS, Inc. (NASDAQ: VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA ® (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.
Sign-up for VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity investment picks
MOUNTAIN VIEW, CA--(Marketwired - November 05, 2014) - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia ®
(phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the third quarter ended September 30, 2014 and provided a business update.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.